Looking to buy the report?


Bone metastasis, also known as "bone mets", occurs when cancer cells break off from a primary tumor that is anywhere else in the body. These cancer cells travel through the blood stream, or lymph system, to a part of the bone and become metastatic cancer cells. This is dissimilar to a primary bone tumor, which normally starts in the bone. When these cancer cells deposit themselves into the bone, they release substances that turn on either osteoclasts or osteoblasts. Osteoclasts will lead to the breakdown of the bone, without a new bone being made, which weakens the bones.

Metastases can occur in any bone in the body, but are most often found in bones near the center of the body. Bones are the third most frequent site of metastases, behind lung and liver. Bone metastasis can occur in any bone, but occurs most commonly in the spine, pelvis, and thigh. Bone metastasis can cause pain and broken bones. The number of people with the bone metastases is rising every year. According to the American Cancer Society, in 2019, approximately 3,500 new cases of bone cancer are expected to be diagnose, and 1,660 deaths are expected to result from these cancers. One way or the other, progress in the treatment of bone metastases is being made through clinical trials. Clinical trials can involve the use of new medications or new methods of treatment. These clinical trials are helping to find the right treatment.

Report Coverage

This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases, and the status of clinical trials, across major regions of the world, are given, with data obtained from multiple sources. The report also comprises a list of key sponsors with pipeline products for the concerned market.

Bone Metastasis Clinical Trial Analysis by Phase and Status

  • The clinical trial analysis for bone metastasis indicates that there are around XX number of trials under various phases
  • Phase X trials accounted for the majority share
  • The trial data analysis suggests a number of ongoing trials, as well as ones that have been terminated

Bone Metastasis Clinical Trials Analysis, by Geography

  • By geography, the scope of the report covers the regional assessment for clinical trials, globally. It covers concise information regarding registered clinical trials in different countries, across several developed and emerging markets
  • The rising number of bone metastasis cases is one of the major driving factor for the market

Key Sponsors in Bone Metastasis Clinical Trials

The report will cover analysis on trails and information on key sponsors, companies, and researchers.

Research Methodology

Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.

Reasons to buy the Report

This report will help you to understand

  • The number of clinical trials that are being conducted worldwide
  • The key products under development (Phase I, Phase II, and Phase III)
  • The main areas of research under development (by product, mechanism of action, molecule, delivery, etc.)
  • The average recruitment size in trials
  • Key deals between institutions and industries
  • Insights on regional- and country-level data
  • Dormant and discontinued studies across the category
  • Information on key sponsors and profiles
  • Protocol and design comparisons, to generate the best solution for your product development strategy

1. Introduction

2. Research Methodology

3. Disease Epidemiology and Trends

4. Healthcare Expenditure and R&D Trends

5. Executive Summary

6. Clinical Trials Segmentation by Phase

                6.1 Phase-III Product Candidates

                6.2 Phase-II Product Candidates

                6.3 Phase-I Product Candidates

7. Clinical Trials, Segmentation by Status

                7.1 Suspended

                7.2 Terminated

                7.3 Withdrawn

                7.4 Ongoing

                7.5 Completed

                7.6 Others

8. Pipeline Therapeutic Assessment (Infographic Charts and a Brief Description)

                8.1. By Clinical Phase and Molecule Type

                8.2. By Clinical Phase and Route of Administration

                8.3 By Sponsor/Collaborator/Institutions

                8.4 By Geography

9. Market Updates

10. Key Sponsor Profiles

11. Sources and Disclaimer

12. About Mordor Intelligence

Looking to buy the report?

Need a report that reflects how COVID-19 has impacted this market and its growth?

Looking to customize report?



By submitting, you confirm that you agree to our privacy policy